Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMimetic Therapeutics, Inc.

http://www.biomimetics.com

Latest From BioMimetic Therapeutics, Inc.

Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow

Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.

Generic Drugs Sales & Earnings

Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings

Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.

Commercial Cancer

US Federal Circuit Refuses To Rehear Arguments In Hatch-Waxman Venue Litigation

Mylan disputed Valeant's complaint in New Jersey federal court for improper venue, on the basis that Valeant firm had no relevant ties to New Jersey and the only alleged act of infringement – submission of the ANDA – did not occur there.

Biocon Biologics CEO Makes Surprise Exit

The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.

Leadership Strategy
See All

Company Information

UsernamePublicRestriction

Register